Atopic Dermatitis

The Future of Atopic Dermatitis Treatment
November 22, 2022

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, explore the impact of recent advances in atopic dermatitis treatment and look to future possibilities.

The Right Type of Patient for JAK Inhibitors
November 22, 2022

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the challenges of identifying the right regimens for patients and the many factors that influence treatment selection.

Conversations With Patients Regarding Safety of JAK Inhibitors
November 22, 2022

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, discuss how to talk about safety concerns with patients.

A New Study Examines the Safety Profiles of JAK Inhibitors for Atopic Dermatitis
November 21, 2022

The author of a new study on JAK inhibitors discusses his surprising findings on the safety profiles of these new medications for dermatologic conditions.

The Latest Buzz in Atopic Dermatitis
November 16, 2022

Experts discuss game-changing drugs and what’s in the pipeline.

Safety and JAK Inhibitors
November 15, 2022

Experts share clinical insights boxed warning for the JAK inhibitor drug class.

The Impact of Itch on Patients With Atopic Dermatitis
November 15, 2022

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, explore the burden of itch in atopic dermatitis, and why JAK inhibitors may be able to provide relief.

The Cutaneous Connection: Treating Atopic Dermatitis in the Winter
November 14, 2022

In this episode, Bernard Cohen, MD, professor of pediatrics and dermatology at Johns Hopkins University School of Medicine, talks about how physicians and patients should treat atopic dermatitis in the winter months, and some new data on treating newborns.

Positive New Results of Tapinarof Cream Study for Pediatric Patients with AD
November 11, 2022

Dermavant announced positive results from its pediatric maximal usage study.

Eli Lilly Submits BLA for Lebrikizumab AD Treatment
November 09, 2022

BLA submission is based on phase 3 trial results evaluating the safety and efficacy of lebrikizumab.